{"id":753836,"date":"2023-05-02T16:28:16","date_gmt":"2023-05-02T20:28:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/"},"modified":"2023-05-02T16:28:16","modified_gmt":"2023-05-02T20:28:16","slug":"spruce-biosciences-to-participate-in-may-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/","title":{"rendered":"Spruce Biosciences to Participate in May Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Spruce Biosciences to Participate in May Investor Conferences<\/b><\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fsprucebiosciences.com%2F&amp;esheet=53391340&amp;newsitemid=20230502005399&amp;lan=en-US&amp;anchor=Spruce+Biosciences%2C+Inc&amp;index=1&amp;md5=2b3ee7a9264ea0272fda654424f9b767\">Spruce Biosciences, Inc<\/a>. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May.<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>The JMP Securities Life Sciences Conference<br \/>\n<br \/><\/b><b>Date:<\/b> May 15-16, 2023<br \/>\n<br \/><b>Format:<\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwsw.com%2Fwebcast%2Fjmp59%2Fsprb%2F1695203&amp;esheet=53391340&amp;newsitemid=20230502005399&amp;lan=en-US&amp;anchor=Fireside+chat&amp;index=2&amp;md5=a07cd0bef7afdd1dad622b5e421adde3\">Fireside chat<\/a> (May 15, 2023 at 1:30 p.m. ET) and 1&#215;1 meetings<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>2023 RBC Capital Markets Global Healthcare Conference<br \/>\n<br \/><\/b><b>Date:<\/b> May 16-17, 2023<br \/>\n<br \/><b>Format:<\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veracast.com%2Fwebcasts%2Frbc%2Fhealthcare2023%2F2PrQ84.cfm&amp;esheet=53391340&amp;newsitemid=20230502005399&amp;lan=en-US&amp;anchor=Fireside+chat&amp;index=3&amp;md5=29f16db2b8fce0f905268a40b9db3f1b\">Fireside chat<\/a> (May 17, 2023 at 3:05 p.m. ET) and 1&#215;1 meetings<\/p>\n<\/li>\n<\/ul>\n<p>\nInterested parties can access the webcast for each conference presentation from the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.sprucebiosciences.com%2Fnews-and-events%2Fevents&amp;esheet=53391340&amp;newsitemid=20230502005399&amp;lan=en-US&amp;anchor=Events&amp;index=4&amp;md5=11fec0e649a14403558965bb613af5db\">Events<\/a> section of the company\u2019s investor relations website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.sprucebiosciences.com%2F&amp;esheet=53391340&amp;newsitemid=20230502005399&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestors.sprucebiosciences.com&amp;index=5&amp;md5=3f9a65f017f9de94e2b43eea5a805afe\">https:\/\/investors.sprucebiosciences.com<\/a>. A replay of the webcasts will be available after the conclusion of the live presentations for approximately 30 days.<\/p>\n<p><b>About Spruce Biosciences<\/b><\/p>\n<p>\nSpruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sprucebiosciences.com&amp;esheet=53391340&amp;newsitemid=20230502005399&amp;lan=en-US&amp;anchor=www.sprucebiosciences.com&amp;index=6&amp;md5=884c846797c2f7625eab04b7b26f96bc\">www.sprucebiosciences.com<\/a> and follow us on Twitter @<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fspruce_bio&amp;esheet=53391340&amp;newsitemid=20230502005399&amp;lan=en-US&amp;anchor=Spruce_Bio&amp;index=7&amp;md5=0d07b51d61485fe537df0d610db6c58a\">Spruce_Bio<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fspruce-biosciences%2F&amp;esheet=53391340&amp;newsitemid=20230502005399&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=9ad64f8aeadd269571e6aca7c9bb78cf\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FSpruceBio%2F&amp;esheet=53391340&amp;newsitemid=20230502005399&amp;lan=en-US&amp;anchor=Facebook&amp;index=9&amp;md5=545fc501f9d8f11e349e1ff02d667904\">Facebook<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUCiPbmokQUFy9wc3wvY5PZnw&amp;esheet=53391340&amp;newsitemid=20230502005399&amp;lan=en-US&amp;anchor=YouTube&amp;index=10&amp;md5=13e12fd0866ab9e6006f1c9c7592ad77\">YouTube<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230502005399\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230502005399\/en\/<\/a><\/span><\/p>\n<p><b>Media Contact<br \/>\n<\/b><br \/>Will Zasadny<br \/>\n<br \/>Evoke Canale<br \/>\n<br \/>(619) 961-8848<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:will.zasadny@evokecanale.com\">will.zasadny@evokecanale.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"mailto:media@sprucebio.com\">media@sprucebio.com<\/a><\/p>\n<p><b>Investors<br \/>\n<\/b><br \/>Xuan Yang<br \/>\n<br \/>Solebury Strategic Communications<br \/>\n<br \/>(415) 971-9412<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:xyang@soleburystrat.com\">xyang@soleburystrat.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"mailto:investors@sprucebio.com\">investors@sprucebio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Hospitals Clinical Trials Biotechnology Other Health Health Pharmaceutical General Health Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230502005399\/en\/789688\/3\/Picture1.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Spruce Biosciences to Participate in May Investor Conferences SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May. The JMP Securities Life Sciences Conference Date: May 15-16, 2023 Format:Fireside chat (May 15, 2023 at 1:30 p.m. ET) and 1&#215;1 meetings 2023 RBC Capital Markets Global Healthcare Conference Date: May 16-17, 2023 Format:Fireside chat (May 17, 2023 at 3:05 p.m. ET) and 1&#215;1 meetings Interested parties can access the webcast for each conference presentation from the Events section of the company\u2019s investor relations website at https:\/\/investors.sprucebiosciences.com. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Spruce Biosciences to Participate in May Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-753836","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Spruce Biosciences to Participate in May Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spruce Biosciences to Participate in May Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Spruce Biosciences to Participate in May Investor Conferences SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May. The JMP Securities Life Sciences Conference Date: May 15-16, 2023 Format:Fireside chat (May 15, 2023 at 1:30 p.m. ET) and 1&#215;1 meetings 2023 RBC Capital Markets Global Healthcare Conference Date: May 16-17, 2023 Format:Fireside chat (May 17, 2023 at 3:05 p.m. ET) and 1&#215;1 meetings Interested parties can access the webcast for each conference presentation from the Events section of the company\u2019s investor relations website at https:\/\/investors.sprucebiosciences.com. &hellip; Continue reading &quot;Spruce Biosciences to Participate in May Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-02T20:28:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spruce Biosciences to Participate in May Investor Conferences\",\"datePublished\":\"2023-05-02T20:28:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/\"},\"wordCount\":296,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/\",\"name\":\"Spruce Biosciences to Participate in May Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-05-02T20:28:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciences-to-participate-in-may-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spruce Biosciences to Participate in May Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spruce Biosciences to Participate in May Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Spruce Biosciences to Participate in May Investor Conferences - Market Newsdesk","og_description":"Spruce Biosciences to Participate in May Investor Conferences SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May. The JMP Securities Life Sciences Conference Date: May 15-16, 2023 Format:Fireside chat (May 15, 2023 at 1:30 p.m. ET) and 1&#215;1 meetings 2023 RBC Capital Markets Global Healthcare Conference Date: May 16-17, 2023 Format:Fireside chat (May 17, 2023 at 3:05 p.m. ET) and 1&#215;1 meetings Interested parties can access the webcast for each conference presentation from the Events section of the company\u2019s investor relations website at https:\/\/investors.sprucebiosciences.com. &hellip; Continue reading \"Spruce Biosciences to Participate in May Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-02T20:28:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spruce Biosciences to Participate in May Investor Conferences","datePublished":"2023-05-02T20:28:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/"},"wordCount":296,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/","name":"Spruce Biosciences to Participate in May Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-05-02T20:28:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230502005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciences-to-participate-in-may-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spruce Biosciences to Participate in May Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=753836"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753836\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=753836"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=753836"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=753836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}